Data for: Post-Marketing Safety Surveillance of Adalimumab, Secukinumab, and Infliximab in Hidradenitis Suppurativa: An Analysis of the FDA Adverse Events Reporting System (FAERS) Database

Published: 12 February 2025| Version 1 | DOI: 10.17632/zrjwzwz65t.1
Contributor:
Aditya Joshi

Description

Supplementary Data for Post-Marketing Safety Surveillance of Adalimumab, Secukinumab, and Infliximab in Hidradenitis Suppurativa: An Analysis of the FDA Adverse Events Reporting System (FAERS) Database

Files

Institutions

University of Washington

Categories

Dermatology, Biologicals, Drug Safety, Hidradenitis Suppurativa

Licence